Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481553 | 0.86 | ALDH1A1 (0.53) | GAAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25920084 | 0.81 | MEN1 (0.43) | GAAEPHX2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12375166 | 0.80 | HSD11B1 (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22156365 | 0.80 | SMN1; SMN2 (0.53) | GAAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25895223 | 0.80 | MEN1 (0.41) | GAAEPHX2MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23342774 | 0.79 | GAA (0.48) | GAAEPHX2MAPTSMN1; SMN2KMT2A | |
| SCHEMBL18389965 | 0.78 | MEN1 (0.38) | GAAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15431472 | 0.76 | EPHX2 (0.34) | GAAEPHX2MAPTMEN1KMT2A | |
| SCHEMBL23185467 | 0.76 | EPHX2 (0.46) | GAAEPHX2MAPTRIPK1ALDH1A1 | |
| SCHEMBL20381994 | 0.76 | MEN1 (0.37) | GAAMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | GAA 905/4885EPHX2 3875/4885MAPT 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.